image
Healthcare - Biotechnology - NASDAQ - US
$ 29.17
-0.647 %
$ 3.52 B
Market Cap
-9.72
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RNA stock under the worst case scenario is HIDDEN Compared to the current market price of 29.2 USD, Avidity Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RNA stock under the base case scenario is HIDDEN Compared to the current market price of 29.2 USD, Avidity Biosciences, Inc. is HIDDEN

This DCF valuation model was last updated on Jul, 6, 2025.

The intrinsic value of one RNA stock under the best case scenario is HIDDEN Compared to the current market price of 29.2 USD, Avidity Biosciences, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart RNA

image
$38.0$38.0$36.0$36.0$34.0$34.0$32.0$32.0$30.0$30.0$28.0$28.0$26.0$26.0$24.0$24.015 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 AprMay '25May '2515 May15 MayJun '25Jun '2515 Jun15 JunJul '25Jul '25
FINANCIALS
10.9 M REVENUE
13.99%
-379 M OPERATING INCOME
-60.84%
-322 M NET INCOME
-51.87%
-301 M OPERATING CASH FLOW
-152.70%
-854 M INVESTING CASH FLOW
-556.72%
1.19 B FINANCING CASH FLOW
1170.30%
1.57 M REVENUE
-47.09%
-132 M OPERATING INCOME
-8.70%
-116 M NET INCOME
-13.22%
-125 M OPERATING CASH FLOW
-24.99%
157 M INVESTING CASH FLOW
344.95%
1.94 M FINANCING CASH FLOW
-85.89%
Balance Sheet Avidity Biosciences, Inc.
image
Current Assets 1.54 B
Cash & Short-Term Investments 1.5 B
Receivables 28.2 M
Other Current Assets 12.6 M
Non-Current Assets 21.6 M
Long-Term Investments 0
PP&E 18.3 M
Other Non-Current Assets 3.32 M
96.01 %Total Assets$1.6b
Current Liabilities 98 M
Accounts Payable 8.46 M
Short-Term Debt 3.84 M
Other Current Liabilities 85.7 M
Non-Current Liabilities 40.9 M
Long-Term Debt 2.96 M
Other Non-Current Liabilities 38 M
6.09 %61.69 %27.32 %Total Liabilities$138.9m
EFFICIENCY
Earnings Waterfall Avidity Biosciences, Inc.
image
Revenue 10.9 M
Cost Of Revenue 0
Gross Profit 10.9 M
Operating Expenses 390 M
Operating Income -379 M
Other Expenses -56.6 M
Net Income -322 M
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)(400m)(400m)11m011m(390m)(379m)57m(322m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
100.00% GROSS MARGIN
100.00%
-3477.43% OPERATING MARGIN
-3477.43%
-2957.71% NET MARGIN
-2957.71%
-22.62% ROE
-22.62%
-20.61% ROA
-20.61%
-25.78% ROIC
-25.78%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Avidity Biosciences, Inc.
image
50m50m00(50m)(50m)(100m)(100m)(150m)(150m)(200m)(200m)(250m)(250m)(300m)(300m)(350m)(350m)20192019202020202021202120222022202320232024202420252025
Net Income -322 M
Depreciation & Amortization 2.78 M
Capital Expenditures -7.07 M
Stock-Based Compensation 51.4 M
Change in Working Capital -14.6 M
Others -67.9 M
Free Cash Flow -308 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Avidity Biosciences, Inc.
image
Wall Street analysts predict an average 1-year price target for RNA of $59 , with forecasts ranging from a low of $59 to a high of $59 .
RNA Lowest Price Target Wall Street Target
59 USD 102.26%
RNA Average Price Target Wall Street Target
59 USD 102.26%
RNA Highest Price Target Wall Street Target
59 USD 102.26%
Price
Max Price Target
Min Price Target
Average Price Target
606055555050454540403535303025252020Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26Jul '26Jul '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 7
6. Ownership
Insider Ownership Avidity Biosciences, Inc.
image
Sold
0-3 MONTHS
1.07 M USD 2
3-6 MONTHS
4.19 M USD 7
6-9 MONTHS
8.38 M USD 5
9-12 MONTHS
15.4 M USD 6
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Avidity Biosciences to Present Topline Data from Phase 1/2 FORTITUDE™ Trial of Del-brax in People Living with Facioscapulohumeral Muscular Dystrophy at 32nd Annual FSHD Society International Research Congress -- FDA alignment on accelerated and full approval pathways for delpacibart braxlosiran  (del-brax) in facioscapulohumeral muscular dystrophy (FSHD) -- -- Jeffrey M. Statland, M.D. prnewswire.com - 1 month ago
Avidity Biosciences Announces Positive Topline Phase 1/2 FORTITUDE™ Data Demonstrating Consistent Improvement Across Multiple Functional Measures Compared to Placebo in Del-Brax Treated FSHD Participants -- Unprecedented data from FORTITUDE™ dose escalation cohorts for del-brax treated participants, compared to placebo, demonstrate improvement in function, strength and PROs as well as rapid and significant reduction in biomarkers -- -- Data support planned accelerated approval BLA submission in H2 2026 -- -- Data being presented at the 32nd Annual FSHD Society International Research Congress (IRC); Investor and analyst webcast event today, Monday, June 9 at 8:00 a.m. ET -- SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced positive topline data from the dose escalation cohorts of the delpacibart braxlosiran (del-brax) Phase 1/2 FORTITUDE™ program in Facioscapulohumeral Muscular Dystrophy (FSHD). prnewswire.com - 1 month ago
Avidity Biosciences Announces the Accelerated Approval Regulatory Pathway in the U.S. is Open for Del-Brax and Initiates the Global, Confirmatory Phase 3 FORWARD™ Study in FSHD -- Planning accelerated approval BLA submission in H2 2026, following topline data fromFORTITUDE™ biomarker cohort in Q2 2026 -- -- Initiated global, confirmatory Phase 3 FORWARD ™ study of del-brax 2mg/kg every six weeks -- -- Investor and analyst webcast event today, Monday, June 9, 2025 at 8 a.m. ET -- SAN DIEGO , June 9, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today announced the accelerated approval regulatory pathway in the United States is open for delpacibart braxlosiran (del-brax) in the treatment of facioscapulohumeral muscular dystrophy (FSHD). prnewswire.com - 1 month ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on May 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 71,000 shares of its common stock and 35,000 restricted stock units ("RSUs") to sixteen (16) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). prnewswire.com - 1 month ago
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates Avidity Biosciences, Inc. (RNA) came out with a quarterly loss of $0.90 per share versus the Zacks Consensus Estimate of a loss of $0.88. This compares to loss of $0.79 per share a year ago. zacks.com - 2 months ago
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights On track to deliver key regulatory updates for del-brax and topline data from dose escalation cohorts in the FORTITUDE™ trial in the second quarter Positive topline del-zota data further supports first BLA submission at year end 2025 – continues to highlight reproducibility and consistency across three late-stage clinical trials for DMD44, DM1 and FSHD  Executing on global commercial infrastructure development and on track with preparations for first potential commercial launch in U.S. in 2026 Strong balance sheet supports execution across three late-stage clinical programs and commercial launch preparations with cash runway into mid-2027 SAN DIEGO , May 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) to profoundly improve people's lives, today reported financial results for the first quarter ended March 31, 2025, highlighting recent progress. "We continue to build on the consistent and reproducible data readouts from our platform across all three of our clinical programs for DMD44, DM1 and FSHD, and are executing on our transition to become a global commercial organization. prnewswire.com - 2 months ago
Avidity Biosciences to Participate in Upcoming Investor Conference SAN DIEGO , May 6, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: Bank of America Securities 2025 Health Care Conference on Tuesday, May 13, 2025, at 3:00 p.m. PT / 6:00 p.m. prnewswire.com - 2 months ago
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) SAN DIEGO , April 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that on April 20, 2025, the Human Capital Management Committee of Avidity's Board of Directors granted non-qualified stock option awards to purchase an aggregate of 263,000 shares of its common stock and 131,450 restricted stock units ("RSUs") to thirty-three (33) new non-executive employees under the Avidity Biosciences, Inc. 2022 Employment Inducement Incentive Award Plan (the "2022 Inducement Plan"). The awards were granted as inducements material to the employees entering into employment with Avidity in accordance with Nasdaq Listing Rule 5635(c)(4). prnewswire.com - 2 months ago
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 Del-desiran first-ever investigational treatment for DM1 to receive Orphan Drug designation in Japan  SAN DIEGO , April 8, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that the Japan Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug designation (ODD) to delpacibart etedesiran (del-desiran) for the treatment of myotonic dystrophy type 1 (DM1), an investigational treatment designed to address the root cause of DM1, an underrecognized, progressive and often fatal neuromuscular disease with no approved therapies. Del-desiran is the first investigational treatment for DM1 to receive Orphan Drug designation in Japan. prnewswire.com - 3 months ago
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? Avidity Biosciences (RNA) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road. zacks.com - 3 months ago
Avidity Biosciences to Participate in Upcoming Investor Conference SAN DIEGO , April 1, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced that Avidity management will participate in a fireside chat during the following investor conference: 24th Annual Needham Virtual Healthcare Conference on Tuesday, April 8, 2025, at 3:00 p.m. ET Live webcast of the event, up-to-date event details and an archived replay will be available on the "Events and Presentations" page in the "Investors" section of Avidity's website at https://aviditybiosciences.investorroom.com/events-and-presentations. prnewswire.com - 3 months ago
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy Del-brax FORTITUDE biomarker cohort designed for potential accelerated approval; plan to share regulatory update in Q2 2025 Regulatory alignment on global Phase 3 del-brax trial design and study initiation anticipated in Q2 2025 Plan to present topline data from FORTITUDE dose escalation cohorts in Q2 2025 On track to be first globally approved drug for FSHD SAN DIEGO , March 31, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced the completion of enrollment in the biomarker cohort in the Phase 1/2 FORTITUDE™ clinical trial of delpacibart braxlosiran (del-brax) in people living with facioscapulohumeral muscular dystrophy (FSHD). A total of 51 participants were enrolled in the FORTITUDE biomarker cohort. prnewswire.com - 3 months ago
8. Profile Summary

Avidity Biosciences, Inc. RNA

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 3.52 B
Dividend Yield 0.00%
Description Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease; AOC 1044 for the treatment of Duchenne Muscular Dystrophy; and AOC 1020 designed to treat facioscapulohumeral muscular dystrophy which are in preclinical stage. It also offers Lumizyme therapy for Pompe diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Contact 10578 Science Center Drive, San Diego, CA, 92121 https://www.aviditybiosciences.com
IPO Date June 12, 2020
Employees 391
Officers Ms. Teresa McCarthy Chief Human Resources Officer Mr. Eric B. Mosbrooker Chief Commercial Officer Mr. Michael F. MacLean CPA Chief Financial Officer Mr. Charles Calderaro III Chief Technical Officer Dr. W. Michael F. Flanagan Ph.D. Chief Scientific Officer Dr. Troy Edward Wilson J.D., Ph.D. Co-Founder & Independent Chairman Ms. Sarah Boyce President, Chief Executive Officer & Director Prof. Mark E. Davis Ph.D. Scientific Founder, Member of Scientific Advisory Board and Member of Board of Managers Mr. John B. Moriarty Jr., ESQ., J.D. Chief Legal Officer & Corporate Secretary Dr. Frank P. McCormick Ph.D. Scientific Founder & Member of Scientific Advisory Board